Global Gastric Cancer Therapeutics Market By Therapy Type (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery), By Disease Indication (Gastric Adenocarcinoma, Gastrointestinal Stromal Tumor, Gastric Neuroendocrine Tumors), By Molecule Type (Small Molecule, Biologics), By Line of Therapy (Neoadjuvant and Adjuvant, First Line Therapy, Second Line Therapy) By Mode of Action (Programmed Cell Death Protein 1 Inhibitors, Human Epidermal Growth Factor Receptor Antagonists, Vascular Endothelial Growth Factor Receptor Antagonists, Others), By Route of Administration, By End User, By Distribution Channel, By Region, Competition Forecast & Opportunities, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 6.62 Billion
CAGR (2026-2031)	13.99%
Fastest Growing Segment	Chemotherapy
Largest Market	North America
Market Size (2031)	USD 14.52 Billion

Market Overview

The Global Gastric Cancer Therapeutics Market will grow from USD 6.62 Billion in 2025 to USD 14.52 Billion by 2031 at a 13.99% CAGR. Gastric cancer therapeutics encompass a diverse range of pharmacological interventions designed to treat malignant neoplasms originating in the stomach lining, including systemic chemotherapy, targeted molecular agents, and immune checkpoint inhibitors. The market trajectory is primarily supported by the rising global prevalence of gastric adenocarcinoma and an aging demographic that naturally correlates with increased disease susceptibility. Furthermore, the expedited regulatory approvals for novel combination therapies have significantly expanded the available treatment landscape and enhanced patient accessibility to potent drug regimens.

Despite these advancements, the sector encounters a significant impediment regarding the frequent diagnosis of the disease at advanced stages which severely limits therapeutic efficacy and patient survival. This difficulty in early detection leads to high mortality rates that constrain the eligible patient population for curative treatments. According to the American Cancer Society, in 2025, estimates projected 30,300 new stomach cancer cases and 10,780 deaths in the United States. This statistic highlights the persistent lethality of the condition and the substantial burden it places on healthcare systems.

Key Market Drivers

The accelerated adoption of targeted therapies and immunotherapies serves as a primary engine for market expansion and fundamentally alters the standard of care for patients with advanced or metastatic disease. Pharmaceutical companies are increasingly prioritizing the development of monoclonal antibodies and antibody-drug conjugates that interact with specific biomarkers such as HER2, CLDN18.2, and PD-L1. This shift towards precision medicine allows clinicians to move beyond non-specific systemic chemotherapy and improves outcomes for biologically defined patient subgroups. According to Astellas Pharma Inc., October 2024, in the 'FDA Approves VYLOY (zolbetuximab-clzb) for Treatment of Advanced Gastric and GEJ Cancer' press release, the pivotal Phase 3 SPOTLIGHT trial showed that the combination of zolbetuximab and mFOLFOX6 significantly extended median progression-free survival to 10.61 months versus the comparator arm. Such clinical milestones underscore the commercial viability and therapeutic necessity of biomarker-directed strategies in the modern treatment paradigm.

The rising global prevalence of gastric adenocarcinoma, particularly within high-incidence regions such as East Asia, further solidifies the demand for effective therapeutic interventions. This geographic concentration of disease burden necessitates a continuous supply of pharmaceutical products and drives strategic market focus toward nations with large patient pools. According to the National Cancer Center of China, February 2024, in the 'Cancer incidence and mortality in China, 2022' report, the country recorded approximately 358,700 new gastric cancer cases, affirming its status as a critical market for drug commercialization. This immense volume of diagnoses exerts pressure on healthcare infrastructure and compels both public and private sectors to invest in accessible treatment options. Furthermore, the global urgency is highlighted by the high mortality associated with the disease. According to the International Agency for Research on Cancer, in 2024, data releases indicated that stomach cancer resulted in an estimated 660,000 deaths worldwide, a statistic that reinforces the critical need for continued innovation in therapeutic development.

Download Free Sample Report

Key Market Challenges

The frequent diagnosis of gastric malignancies at advanced, metastatic stages constitutes a primary challenge hampering the growth of the "Global Gastric Cancer Therapeutics Market." Because early-stage tumors often develop asymptomatically, a large proportion of patients present with disease that has already progressed beyond the scope of curative intervention. This delayed detection severely restricts the commercial potential of therapeutics by shortening the window of treatment opportunity and limiting the eligibility for long-term maintenance regimens. Instead of extended courses of curative therapy, treatment often shifts to palliative care with shorter durations, thereby reducing the overall volume of drug utilization.

This constraint is reflected in the high mortality-to-incidence ratio, which rapidly depletes the addressable patient population. According to the World Health Organization, in 2024, gastric cancer was responsible for approximately 660,000 deaths worldwide compared to 970,000 new cases. Such statistics underscore the lethality associated with late-stage diagnosis, which fundamentally limits the expansion of the market by preventing the accumulation of a chronic prevalence pool required for sustained revenue growth in the therapeutics sector.

Key Market Trends

The Rapid Adoption of Antibody-Drug Conjugates (ADCs) is reshaping the sector as these therapies transition from niche options to substantial revenue generators. This trend is driven by the commercial dominance of HER2-directed agents, which are capturing market share by delivering superior efficacy over traditional chemotherapy. The significant financial performance of these biologics validates the high-value potential of ADC platforms and incentivizes further innovation. According to Daiichi Sankyo, February 2025, in the 'Oncology Business Briefing FY2024', Enhertu global net sales reached 143.1 billion JPY in the third quarter of fiscal year 2024, highlighting the accelerating demand for this drug class.

The Integration of FGFR2b-Targeted Agents in Clinical Pipelines marks a critical diversification of the treatment landscape, expanding precision medicine beyond established HER2 markers. This development addresses a significant unmet need for patients with specific biomarker profiles, effectively broadening the addressable market for targeted interventions. Pharmaceutical companies are heavily investing in late-stage trials to validate these novel agents for first-line regimens. According to Amgen, June 2025, in the 'Amgen Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer' press release, the pivotal FORTITUDE-101 trial enrolled 547 patients, confirming the scale of development efforts in this emerging segment.

Segmental Insights

Based on recent market intelligence, Chemotherapy is highlighted as the fastest growing segment in the Global Gastric Cancer Therapeutics Market, primarily due to its evolving role as the foundational backbone for innovative combination treatments. Its rapid expansion is driven by recent approvals from regulatory bodies like the FDA for regimens that pair chemotherapy with advanced immunotherapies, establishing these combinations as the new standard of care for first-line treatment. Furthermore, the high prevalence of gastric cancer in emerging economies continues to fuel the surge in chemotherapy prescription volumes owing to its cost-effectiveness and widespread clinical accessibility compared to monotherapies.

Regional Insights

North America maintains a leading position in the Global Gastric Cancer Therapeutics Market, driven by its well-established healthcare infrastructure and significant investment in research and development. The presence of major pharmaceutical firms fosters continuous innovation and clinical trials within the region. Additionally, favorable regulatory environments, such as those overseen by the U.S. Food and Drug Administration, streamline the approval process for new treatments. Strong reimbursement coverage further supports patient access to therapies, ensuring consistent market growth and dominance.

Recent Developments

• In March 2025, Merck received traditional approval from the U.S. Food and Drug Administration for Keytruda (pembrolizumab) in combination with trastuzumab and chemotherapy. The approval indicated the therapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumors expressed PD-L1 with a combined positive score of 1 or higher. The decision converted a previous accelerated approval into a full approval following the demonstrated efficacy in overall survival and progression-free survival in the Phase 3 KEYNOTE-811 clinical trial, reaffirming the regimen's clinical benefit in this setting.
• In November 2024, BeiGene announced that the European Commission granted marketing authorization for Tevimbra (tislelizumab) in combination with chemotherapy for the first-line treatment of adult patients with HER2-negative locally advanced, unresectable, or metastatic gastric or gastroesophageal junction adenocarcinoma. The approval was supported by data from the Phase 3 RATIONALE-305 trial, which demonstrated a statistically significant and clinically meaningful survival benefit for patients treated with the immunotherapy combination compared to placebo. This regulatory milestone significantly expanded the company's portfolio in Europe, offering a new standard of care option for patients suffering from advanced gastric cancer.
• In October 2024, Astellas Pharma received approval from the U.S. Food and Drug Administration for Vyloy (zolbetuximab-clzb) in combination with fluoropyrimidine- and platinum-containing chemotherapy. This approval authorized the treatment for adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors were CLDN18.2 positive. The regulatory decision was based on results from the Phase 3 SPOTLIGHT and GLOW clinical trials, which showed statistically significant improvements in progression-free survival and overall survival, establishing the drug as the first and only CLDN18.2-targeted therapy available in the United States market for this specific patient population.
• In July 2024, ALX Oncology announced positive topline results from the Phase 2 ASPEN-06 clinical trial evaluating evorpacept for the treatment of HER2-positive gastric cancer. The study demonstrated that evorpacept, a CD47-blocking therapeutic, in combination with trastuzumab, ramucirumab, and paclitaxel, achieved a confirmed overall response rate of 40.3% compared to 26.6% for the control group. The data indicated a clinically meaningful improvement in the duration of response and maintained a tolerable safety profile, validating the mechanism of action of the company's lead candidate in effectively targeting solid tumors and addressing the unmet medical needs of patients with advanced gastric malignancies.

Key Market Players

• AstraZeneca PLC
• F. Hoffmann-La Roche AG
• Novartis AG
• Merck & Co., Inc.
• Pfizer Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Takeda Pharmaceutical Company Limited
• Sanofi S.A.
• GlaxoSmithKline plc

By Therapy Type	By Disease Indication	By Molecule Type	By Line of Therapy	By Mode of Action	By Region
Chemotherapy Targeted Therapy Immunotherapy Radiation Therapy Surgery	Gastric Adenocarcinoma Gastrointestinal Stromal Tumor Gastric Neuroendocrine Tumors	Small Molecule Biologics	Neoadjuvant and Adjuvant First Line Therapy Second Line Therapy	Programmed Cell Death Protein 1 Inhibitors Human Epidermal Growth Factor Receptor Antagonists Vascular Endothelial Growth Factor Receptor Antagonists Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Gastric Cancer Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Gastric Cancer Therapeutics Market, By Therapy Type:

• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Radiation Therapy
• Surgery

• Gastric Cancer Therapeutics Market, By Disease Indication:

• Gastric Adenocarcinoma
• Gastrointestinal Stromal Tumor
• Gastric Neuroendocrine Tumors

• Gastric Cancer Therapeutics Market, By Molecule Type:

• Small Molecule
• Biologics

• Gastric Cancer Therapeutics Market, By Line of Therapy:

• Neoadjuvant and Adjuvant
• First Line Therapy
• Second Line Therapy

• Gastric Cancer Therapeutics Market, By Mode of Action:

• Programmed Cell Death Protein 1 Inhibitors
• Human Epidermal Growth Factor Receptor Antagonists
• Vascular Endothelial Growth Factor Receptor Antagonists
• Others

• Gastric Cancer Therapeutics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE